{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"crizotinib-resistant advanced ALK-positive NSCLC","name":"ALTA-3","nct_id":"NCT03596866","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=alta-3-nct03596866. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ALTA-3","arms":[{"description":"Participants were administered brigatinib 90 milligrams (mg), tablets, orally, once daily (QD) for 7 days, followed by brigatinib 180 mg, tablets, orally, QD until objective disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), as assessed by the investigator, or intolerable toxicity, or up to 63.47 months.","label":"Brigatinib","type":"EXPERIMENTAL"},{"description":"Participants were administered alectinib 600 mg, capsules, orally, twice daily (BID) until objective disease progression per RECIST v1.1, as assessed by the investigator, or intolerable toxicity, or up to 59.83 months.","label":"Alectinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-09-18","type":"ACTUAL"},"conditions":["ALK+ Advanced NSCLC"],"enrollment":{"count":248,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Brigatinib","otherNames":["Alunbrig"],"type":"DRUG"},{"name":"Alectinib","otherNames":["Alecensa"],"type":"DRUG"}],"last_update":"2025-09-12","lead_sponsor":"Takeda","official_title":"A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1","timeFrame":"Up to 33.8 months"}],"references":[{"citation":"Yang JC, Liu G, Lu S, He J, Burotto M, Ahn MJ, Kim DW, Liu X, Zhao Y, Vincent S, Yin J, Ma X, Lin HM, Popat S. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12.","pmid":"37574132","type":"DERIVED"},{"citation":"Popat S, Liu G, Lu S, Song G, Ma X, Yang JC. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncol. 2021 Nov;17(32):4237-4247. doi: 10.2217/fon-2021-0608. Epub 2021 Aug 23.","pmid":"34423676","type":"DERIVED"}],"start_date":{"date":"2019-04-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03596866"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/alta-3-nct03596866"}